Clearside Biomedical (CLSD) Releases Quarterly Earnings Results, Misses Expectations By $0.12 EPS

Clearside Biomedical (NASDAQ:CLSD) issued its quarterly earnings results on Thursday. The company reported ($0.75) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.63) by ($0.12), Fidelity Earnings reports.

NASDAQ:CLSD traded down $0.14 on Friday, reaching $1.84. 707,532 shares of the stock traded hands, compared to its average volume of 703,408. The firm has a market cap of $70.13 million, a P/E ratio of -0.79 and a beta of -3.98. The company has a debt-to-equity ratio of 0.15, a quick ratio of 7.94 and a current ratio of 7.94. Clearside Biomedical has a 12 month low of $1.83 and a 12 month high of $15.33.

A number of large investors have recently added to or reduced their stakes in CLSD. Northpointe Capital LLC bought a new stake in Clearside Biomedical during the 2nd quarter valued at about $8,725,000. BlackRock Inc. increased its stake in Clearside Biomedical by 53.1% during the 2nd quarter. BlackRock Inc. now owns 1,859,948 shares of the company’s stock valued at $19,883,000 after purchasing an additional 645,292 shares in the last quarter. JPMorgan Chase & Co. increased its stake in Clearside Biomedical by 712.5% during the 3rd quarter. JPMorgan Chase & Co. now owns 289,626 shares of the company’s stock valued at $1,781,000 after purchasing an additional 253,981 shares in the last quarter. AWM Investment Company Inc. increased its stake in Clearside Biomedical by 31.6% during the 3rd quarter. AWM Investment Company Inc. now owns 875,126 shares of the company’s stock valued at $5,382,000 after purchasing an additional 210,131 shares in the last quarter. Finally, Point72 Asset Management L.P. bought a new stake in Clearside Biomedical during the 2nd quarter valued at about $2,138,000. Institutional investors and hedge funds own 62.23% of the company’s stock.

Several research analysts recently issued reports on the stock. BidaskClub lowered shares of Clearside Biomedical from a “buy” rating to a “hold” rating in a research note on Friday, July 20th. Zacks Investment Research upgraded shares of Clearside Biomedical from a “sell” rating to a “hold” rating in a research note on Monday, August 13th. Laidlaw assumed coverage on shares of Clearside Biomedical in a research note on Monday, July 16th. They issued a “buy” rating and a $18.00 price target for the company. Cowen lowered shares of Clearside Biomedical from an “outperform” rating to a “market perform” rating in a research note on Monday, November 5th. Finally, Stifel Nicolaus reiterated a “hold” rating and issued a $4.00 price target (down from $20.00) on shares of Clearside Biomedical in a research note on Monday, November 5th. Three analysts have rated the stock with a sell rating, two have issued a hold rating and six have issued a buy rating to the company’s stock. Clearside Biomedical currently has a consensus rating of “Hold” and a consensus target price of $12.71.

COPYRIGHT VIOLATION NOTICE: This news story was posted by The Lincolnian Online and is owned by of The Lincolnian Online. If you are reading this news story on another domain, it was illegally copied and reposted in violation of US & international trademark and copyright law. The legal version of this news story can be accessed at https://www.thelincolnianonline.com/2018/11/10/clearside-biomedical-clsd-releases-quarterly-earnings-results-misses-expectations-by-0-12-eps.html.

Clearside Biomedical Company Profile

Clearside Biomedical, Inc, a late-stage clinical biopharmaceutical company, develops pharmacological therapies to treat blinding diseases of the eye. It is developing suprachoroidal injection of CLS-TA, a proprietary preservative-free formulation of the corticosteroid triamcinolone acetonide, which is in Phase III clinical trial for the treatment of macular edema associated with non-infectious uveitis; suprachoroidal injection of CLS-TA and a concomitant intravitreal injection of Eylea, an inhibitor of vascular endothelial growth factor that is in Phase III clinical trial to treat macular edema associated with retinal vein occlusion; and suprachoroidal injection of CLS-TA alone or together with intravitreal injection of Eylea that is in phase II clinical trial for diabetic macular edema.

Recommended Story: Risk Tolerance and Your Investment Decisions

Earnings History for Clearside Biomedical (NASDAQ:CLSD)

Receive News & Ratings for Clearside Biomedical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clearside Biomedical and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply